PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy

Neoplasm Metastasis Clinical Trial

Official title:

PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01696565
• Other study ID #: PH-CP002-2
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: December 2001
• Est. completion date: October 2003

Study information

• Verified date: November 2023
• Source: PhytoHealth Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objectives of this Phase I/II study are:

1. To find out the maximum tolerated dose (MTD) of PG2 in patients with advanced malignancy receiving chemotherapy and to define a "Study Dose" for Phase II.

2. To evaluate the hematopoietic and immunological responses after administering of PG2. Primarily to study the biological response of PG2, defined as WBC count in this study, and secondarily to study the immunological factors, IL-2, IL-6, TGF-beta, and G-CSF.

Description:

This study is the first step for PG2 clinical development in Taiwan in order to further establish its safety and efficacy profile and to build the basis for larger trials.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: October 2003
• Est. primary completion date: October 2003
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patient must have malignancy with metastatic or recurrent diseases.

• Patient must have a minimum of thirteen days period elapsed from any previous chemotherapy or radiotherapy and all treatment-related toxicities subsided.

• Patient must have at least 2 courses of chemotherapy treatment left, and a minimum of 13 days between the administration of the last dose of the chemotherapy with PG2 and the start of the next course of chemotherapy.

• Performance status is 0-2 by ECOG scale.

• Patient's compliance and geographic proximity that allow adequate follow up.

• Adequate bone marrow function before the chemotherapy

• Adequate liver and renal function before the chemotherapy

• Written informed consent from patients

• Woman with childbearing potential should use contraception method through the whole PG2 treatment course.

• After the previous course of chemotherapy, the nadir of WBC dropped between 1000 to 3000/ mm3 (for phase II only).

Exclusion Criteria:

• PG2 skin test is positive.

• Active infection

• Breast feeding

• Prior radiotherapy more than 30% of the bone marrow involved.

• Pregnant woman

• Bone marrow transplantation or brain disease

Related Conditions & MeSH terms

• Neoplasm Metastasis
• Neoplasm Recurrence
• Neoplasms
• Recurrence

Intervention

Drug:
• PG2
Injectable

Locations

Country	Name	City	State
Taiwan	Tri-Service General Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
PhytoHealth Corporation

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase I: To find the maximum tolerated dose (MTD) or the highest tolerated dose (HTD) as the study dose of PG2; Phase II: To use the study dose and assess the WBC level of PG2	For phase I study, the primary endpoint is to determine a safe dosage of PG2 by the dose escalation design.; For phase II study, the primary endpoint is to compare the WBC level between PG2 plus chemotherapy and chemotherapy alone.	within 14 days of each chemotherapy cycle
Secondary	Phase II: To use the study dose to assess the hematopoietic and immunological cytokine levels	For phase II study, the secondary endpoint is to compare the levels of IL-2, IL-6, TGF-beta and G-CSF between PG2 plus chemotherapy and chemotherapy alone.	within 14 days of each chemotherapy cycle